These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32021076)

  • 1. Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies.
    Shen Lee B; Kabat AG; Bacharach J; Karpecki P; Luchs J
    Clin Ophthalmol; 2020; 14():119-126. PubMed ID: 32021076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.
    Sheppard J; Shen Lee B; Periman LM
    Ann Med; 2023 Dec; 55(1):241-252. PubMed ID: 36576348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians.
    Verjee MA; Brissette AR; Starr CE
    Ophthalmol Ther; 2020 Dec; 9(4):877-888. PubMed ID: 33090327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental Pharmacotherapy for Dry Eye Disease: A Review.
    Baiula M; Spampinato S
    J Exp Pharmacol; 2021; 13():345-358. PubMed ID: 33790661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Management of Dry Eye Disease: Beyond Artificial Tears.
    Matossian C; Crowley M; Periman L; Sorkin S
    Clin Ophthalmol; 2022; 16():3911-3918. PubMed ID: 36452043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
    Schechter BA; Urbieta M; Bacharach J; Toyos M; Smyth-Medina R; Mitchell B; Luchs JI
    Clin Ophthalmol; 2022; 16():4145-4151. PubMed ID: 36536927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye.
    Hovanesian JA; Keyser A; Berdy G; Sorensen R
    Clin Ophthalmol; 2022; 16():3841-3849. PubMed ID: 36438591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated Tear Fluid Nociception-Associated Factors, Corneal Dendritic Cell Density, and Vitamin D Levels in Evaporative Dry Eye.
    Khamar P; Nair AP; Shetty R; Vaidya T; Subramani M; Ponnalagu M; Dhamodaran K; D'souza S; Ghosh A; Pahuja N; Deshmukh R; Ahuja P; Sainani K; Nuijts RMMA; Das D; Ghosh A; Sethu S
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2532-2542. PubMed ID: 31195410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry Eye Disease: Consideration for Women's Health.
    Matossian C; McDonald M; Donaldson KE; Nichols KK; MacIver S; Gupta PK
    J Womens Health (Larchmt); 2019 Apr; 28(4):502-514. PubMed ID: 30694724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops.
    Srinivasan S; Manoj V
    Clin Ophthalmol; 2021; 15():2421-2435. PubMed ID: 34135570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry Eye Disease: Focus on Prescription Therapy.
    Marshall LL; Hayslett RL
    Sr Care Pharm; 2023 Jun; 38(6):239-251. PubMed ID: 37231571
    [No Abstract]   [Full Text] [Related]  

  • 12. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments.
    Periman LM; Mah FS; Karpecki PM
    Clin Ophthalmol; 2020; 14():4187-4200. PubMed ID: 33299295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry eye disease: pathophysiology, classification, and diagnosis.
    Perry HD
    Am J Manag Care; 2008 Apr; 14(3 Suppl):S79-87. PubMed ID: 18452371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scleral Lenses for Managing Dry Eye Disease in the Absence of Corneal Irregularities: What Is the Current Evidence?
    Qiu SX; Fadel D; Hui A
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
    Shen Lee B; Toyos M; Karpecki P; Schiffbauer J; Sheppard J
    Ophthalmol Ther; 2022 Aug; 11(4):1333-1369. PubMed ID: 35608780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry Eye Disease: Present Challenges in the Management and Future Trends.
    Al-Saedi Z; Zimmerman A; Bachu RD; Dey S; Shah Z; Baugh R; Boddu SH
    Curr Pharm Des; 2016; 22(28):4470-90. PubMed ID: 27296759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress of nanomedicine in managing dry eye disease.
    Lv Z; Li S; Zeng G; Yao K; Han H
    Adv Ophthalmol Pract Res; 2024; 4(1):23-31. PubMed ID: 38356795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Dry Eye Symptoms: Current Trends and Issues of Dry Eye Questionnaires in Japan.
    Shiraishi A; Sakane Y
    Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES23-DES28. PubMed ID: 30481802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.